Table 3. Adverse events.
| Variables | Apatinib plus S-1 (n=43) | Regorafenib (n=36) | Fruquintinib (n=35) | |||||
|---|---|---|---|---|---|---|---|---|
| All grades | Grade 3–4 | All Grades | Grade 3–4 | All Grades | Grade 3–4 | |||
| Clinical adverse event, n (%) | ||||||||
| Fatigue | 13 (30.2) | 1 (2.3) | 17 (47.2) | 5 (13.9) | 6 (17.1) | 1 (2.9) | ||
| Hypertension | 11 (25.6) | 4 (9.3) | 8 (22.2) | 3 (8.3) | 16 (45.7) | 5 (14.3) | ||
| Loss of appetite | 14 (32.6) | 0 | 10 (27.8) | 2 (5.6) | 7 (20.0) | 0 | ||
| Oral mucositis | 4 (9.3) | 0 | 2 (5.6) | 0 | 1 (2.9) | 0 | ||
| HFSR | 12 (27.9) | 3 (7.0) | 21 (58.3) | 5 (13.9) | 14 (40.0) | 3 (8.6) | ||
| Bleeding | 1 (2.3) | 0 | 2 (5.6) | 0 | 1 (2.9) | 0 | ||
| Laboratory abnormalities, n (%) | ||||||||
| Thrombocytopenia | 17 (39.5) | 0 | 10 (27.8) | 1 (2.8) | 7 (20.0) | 0 | ||
| Anemia | 27 (62.8) | 0 | 20 (55.6) | 2 (5.6) | 11 (31.4) | 0 | ||
| Neutropenia | 13 (30.2) | 1 (2.3) | 3 (8.3) | 0 | 2 (5.7) | 1 (2.9) | ||
| ALT elevation | 10 (23.3) | 0 | 8 (22.2) | 0 | 5 (14.3) | 0 | ||
| Proteinuria | 12 (27.9) | 0 | 12 (33.3) | 0 | 11 (31.4) | 0 | ||
HFSR, hand-foot-skin reaction; ALT, alanine transaminase.